Northwestern Mutual Wealth Management Co. Has $4.63 Million Stake in Ultragenyx Pharmaceutical Inc. $RARE

Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 670,396.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 201,149 shares of the biopharmaceutical company’s stock after purchasing an additional 201,119 shares during the period. Northwestern Mutual Wealth Management Co.’s holdings in Ultragenyx Pharmaceutical were worth $4,626,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Aquatic Capital Management LLC increased its holdings in Ultragenyx Pharmaceutical by 79.1% during the 3rd quarter. Aquatic Capital Management LLC now owns 191,458 shares of the biopharmaceutical company’s stock valued at $5,759,000 after purchasing an additional 84,559 shares in the last quarter. Thornburg Investment Management Inc. acquired a new stake in Ultragenyx Pharmaceutical during the 3rd quarter valued at $2,083,000. Aberdeen Group plc increased its holdings in Ultragenyx Pharmaceutical by 94.3% during the 3rd quarter. Aberdeen Group plc now owns 973,656 shares of the biopharmaceutical company’s stock valued at $29,288,000 after purchasing an additional 472,600 shares in the last quarter. WCM Investment Management LLC increased its holdings in Ultragenyx Pharmaceutical by 36.9% during the 3rd quarter. WCM Investment Management LLC now owns 288,109 shares of the biopharmaceutical company’s stock valued at $8,747,000 after purchasing an additional 77,640 shares in the last quarter. Finally, Rafferty Asset Management LLC increased its holdings in Ultragenyx Pharmaceutical by 93.0% during the 3rd quarter. Rafferty Asset Management LLC now owns 156,484 shares of the biopharmaceutical company’s stock valued at $4,707,000 after purchasing an additional 75,388 shares in the last quarter. 97.67% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CEO Emil D. Kakkis sold 54,404 shares of the firm’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total value of $1,240,411.20. Following the transaction, the chief executive officer directly owned 658,994 shares in the company, valued at $15,025,063.20. This trade represents a 7.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Erik Harris sold 10,539 shares of the firm’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total value of $240,289.20. Following the completion of the transaction, the executive vice president owned 89,515 shares in the company, valued at $2,040,942. This represents a 10.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 117,262 shares of company stock worth $2,687,403 over the last three months. Insiders own 5.20% of the company’s stock.

Ultragenyx Pharmaceutical Stock Performance

Shares of RARE opened at $23.39 on Friday. The firm has a market capitalization of $2.30 billion, a price-to-earnings ratio of -3.83 and a beta of 0.39. The business’s fifty day moving average price is $23.22 and its two-hundred day moving average price is $26.12. Ultragenyx Pharmaceutical Inc. has a 52 week low of $18.29 and a 52 week high of $42.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.49) by ($0.35). Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 91.03%.The company had revenue of $136.00 million during the quarter, compared to the consensus estimate of $158.19 million. During the same quarter in the prior year, the business earned ($1.57) earnings per share. The firm’s revenue for the quarter was down 2.2% on a year-over-year basis. As a group, research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -4.62 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on RARE. Wall Street Zen lowered Ultragenyx Pharmaceutical from a “hold” rating to a “strong sell” rating in a research report on Monday, May 11th. JPMorgan Chase & Co. decreased their price objective on Ultragenyx Pharmaceutical from $120.00 to $74.00 and set an “overweight” rating on the stock in a research report on Thursday, March 12th. Cantor Fitzgerald increased their price objective on Ultragenyx Pharmaceutical from $84.00 to $96.00 and gave the company an “overweight” rating in a research report on Thursday. Wedbush decreased their price objective on Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. Finally, Guggenheim decreased their price objective on Ultragenyx Pharmaceutical from $52.00 to $43.00 and set a “buy” rating on the stock in a research report on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $59.88.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.